
    
      This is a single-center, open-label, randomized, two way crossover design, pharmacokinetics
      study.

        1. Treatment A: study agents (Rifater+EMB) will be given approximately 45 minutes prior to
           breakfast.

        2. Treatment B: study agents (Rifater+EMB) will be given approximately 45 minutes after the
           breakfast is finished.
    
  